BioMarin Retains Outperform Rating and 4 Stock Analyses Sparking Chatter
MetLife, Inc. (NYSE:MET): RBC Capital views the changes to MetLife’s (NYSE:MET) bank sale terms as positive for their stock in the short-term, but believes the news will not provide a sustained rally. RBC is not sure if the Federal Deposit Insurance Corporation (FDIC) will accept the new terms or challenge them in court. The firm raised their price target for MetLife shares from $45 to $47 and maintains a Sector Perform rating on the name.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): RBC Capital believes that Phase II PEG-PAL data and Phase I Achondroplasia safety data could be announced next week, and may push BioMarin Pharmaceuticals Inc. shares higher. The firm keeps an Outperform rating on their shares.
Advanced Micro Devices, Inc. (NYSE:AMD): After their industry checks suggested that the company is facing increasing competitive and end-market challenges, JMP Securities lowered their estimates for Advanced Micro Devices, Inc. JMP cut their price target for shares, from $4 to $2 and keeps an Underperform rating on the stock.
Discover Financial Services (NYSE:DFS): Jefferies believes that Discover Financial Service’s agreement with the Council for Fair Business Practices (CFBP) and Federal Deposit Insurance Corporation (FDIC)has removed a modest overhang. The firm expects the company’s credit to continue improving and raised their price target for shares from $40 to $45. A Buy rating is kept on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>